Inflammation and oxidative stress are pathogenic mediators of many diseases, but molecules that could be therapeutic targets remain elusive. Inflammation and matrix degradation in the vasculature are crucial for abdominal aortic aneurysm (AAA) formation. Cyclophilin A (CypA, encoded by Ppia) is highly expressed in vascular smooth muscle cells (VSMCs), is secreted in response to reactive oxygen species (ROS) and promotes inflammation. Using the angiotensin II (AngII)-induced AAA model in Apoe À/À mice, we show that Apoe À/À Ppia À/À mice are completely protected from AngII-induced AAA formation, in contrast to Apoe À/À Ppia +/+ mice. Apoe À/À Ppia À/À mice show decreased inflammatory cytokine expression, elastic lamina degradation and aortic expansion. These features were not altered by reconstitution of bone marrow cells from Ppia +/+ mice. Mechanistic studies showed that VSMC-derived intracellular and extracellular CypA are required for ROS generation and matrix metalloproteinase-2 activation. These data define a previously undescribed role for CypA in AAA formation and suggest CypA as a new target for treating cardiovascular disease.
RESULTS
CypA deficiency blocks AngII-induced AAA formation in vivo As previously reported 4, 16, 24, 25 , we found that treatment with AngII for 4 weeks promotes AAA formation in Apoe À/À mice ( Fig. 1a-c) .
To determine the role of CypA in AAA formation, we established Apoe À/À Ppia À/À (double-knockout) mice and treated them with AngII for 4 weeks. AngII treatment increased systolic blood pressure and total cholesterol levels, but these parameters did not differ between Apoe À/À mice and Apoe À/À Ppia À/À mice ( Supplementary  Table 1a online). There were no gross differences in morphology between the aortas of control Apoe À/À and Apoe À/À Ppia À/À mice (saline-infused mice, Fig. 1a ). Notably, after AngII infusion, none of the Apoe À/À Ppia À/À mice developed AAA, in contrast to 78% AAA incidence in Apoe À/À mice (Fig. 1a,b ). There was also a significant decrease in maximal aortic diameter ( Fig. 1c ) and aortic weight ( Supplementary Table 1a ) in AngII-treated Apoe À/À Ppia À/À mice compared to AngII-treated Apoe À/À mice. These results suggest that CypA is required for AAA formation induced by AngII.
Morphologically, the aortas of Apoe À/À Ppia À/À mice infused with saline ( Fig. 1d-f ) did not differ from those of control Apoe À/À mice (data not shown). In Apoe À/À mice infused with AngII ( Fig. 1d-f ), there was a marked increase in the sizes of both the aortic lumen and wall. The aortic wall developed a tissue mass composed of organized thrombus, small blood vessels, extracellular matrix and spindle-shaped cells, as described previously 24 . Most of the cells that expressed CypA (Fig. 1e) concomitantly showed immunoreactivity for a-smooth muscle actin (a-SMA, Fig. 1f ), suggesting that they were VSMCs 19 .
In contrast, the aortas of Apoe À/À Ppia À/À mice infused with AngII showed no substantial increase in aortic wall thickness ( Fig. 1d-f ). These results suggest that CypA deficiency confers protection from the early stages of AAA formation.
Over the 4 weeks of the experiment, 35% of the Apoe À/À mice infused with AngII died, whereas none of the Apoe À/À Ppia À/À mice did ( Supplementary Fig. 1a online) . Gross and histological examination of the dead mice revealed aortic rupture ( Supplementary  Fig. 1b-d) . As expected, the elastic lamina was frequently disrupted and degraded in Apoe À/À mice ( Supplementary Fig. 1e ). In contrast, CypA deficiency completely prevented elastic lamina degradation ( Supplementary Fig. 1f ). On the basis of a semiquantitative analysis of elastin degradation ( Supplementary Fig. 1g ), CypA deficiency completely blocked elastin degradation after AngII treatment for 4 weeks ( Supplementary Fig. 1h ). These data suggest that protection from elastin degradation is a major mechanism for the inhibition of AAA formation in Apoe À/À Ppia À/À mice.
To ascertain whether AngII-induced vascular inflammation is CypA dependent, we examined inflammatory cell migration and microvessel formation. Inflammatory cell migration, as assessed by CD45 + cell number, was significantly reduced in Apoe À/À Ppia À/À mice compared with Apoe À/À mice ( Fig. 2a-c) . The number of microvessels in the aortic wall was also markedly lower in Apoe À/À Ppia À/À mice ( Fig. 2d-h) , consistent with the reduced inflammatory response.
To characterize the mechanisms by which CypA participates in the inflammatory response, we first analyzed the secretion of proinflammatory cytokines and chemokines in vitro. AngII treatment of VSMCs strongly induced the secretion of proinflammatory cytokines such as monocyte chemoattractant protein-1 (MCP-1) and interleukin-6, as well as chemokines such as regulated CC motif chemokine ligand-5 (CCL5) and stromal cell-derived factor-1, whereas secretion of these factors was effectively blocked by CypA deficiency ( Supplementary  Fig. 2a online). We next showed that AngII stimulated CypA secretion in mouse aortic VSMCs (Fig. 2i ). CypA secretion was maximal at 1 mM AngII (Fig. 2i ). Pretreatment with Y27632 (a Rho kinase inhibitor) or simvastatin markedly reduced CypA secretion ( Fig. 2i) , which is consistent with our previous report 21 . We studied MCP-1 expression in the aortic wall because of the known role of MCP-1 in macrophage migration and AAA formation 24, 26 . In the medial layer of saline-infused aortas, MCP-1 was more highly expressed in Apoe À/À aortas compared to Apoe À/À Ppia À/À aortas ( Supplementary  Fig. 2b,c) . MCP-1 was highly expressed in the aortas of AngII-treated Apoe À/À mice ( Supplementary Fig. 2d ), especially in the adventitia, but was not as highly expressed in aortas from AngII-treated Apoe À/À Ppia À/À mice ( Supplementary Fig. 2e ). The adventitial location of MCP-1 expression in response to AngII treatment is consistent with the function of MCP-1 as a chemoattractant for monocytes. Additionally, in cultured aortic VSMCs, AngII-stimulated MCP-1 CypA deficiency prevents AngII-induced AAA formation. Apoe À/À and Apoe À/À Ppia À/À mice were infused with AngII or saline for 4 weeks.
(a) Representative photographs showing macroscopic features of aneurysms induced by AngII. The arrows indicate typical AAAs in Apoe À/À mice. Scale bars, 1 mm. (b) The incidence of AngII-induced AAA in Apoe À/À Ppia À/À mice (n ¼ 15) compared with Apoe À/À mice (n ¼ 18). There was no AAA formation in the control group (saline infusion) in both Apoe À/À (n ¼ 4) and Apoe À/À Ppia À/À mice (n ¼ 4). *P o 0.01 compared with AngII-infused Apoe À/À mice. secretion was markedly decreased in Ppia À/À cells compared to Ppia +/+ cells ( Supplementary Fig. 2f ), whereas other AngII signaling events such as activation of extracellular signal-related kinases 1 and 2 (commonly referred to as ERK1/2) did not differ.
Vascular CypA is essential for AAA formation CypA has been reported to have a crucial role in regulating the survival, proliferation and differentiation of antigen-presenting cells by augmenting antigen uptake and presentation 27 . CypA has also been reported to stimulate migration of bone marrow-derived cells in vitro 22 . Hematopoietic cells, especially macrophages, are involved in AAA formation 4, 24 . We hypothesized that CypA deficiency may impair macrophage differentiation and activation and thus prevent AAA formation by AngII. To test this possibility, we transplanted Apoe +/+ Ppia +/+ GFP + bone marrow cells into irradiated Apoe À/À or Apoe À/À Ppia À/À mice. After 42 d of engraftment, we treated the mice with AngII. There was no significant difference in the reconstitution ratio (percentage of GFP + cells in the peripheral blood) in GFP + marrow-transplanted Apoe À/À Ppia À/À mice compared with GFP + marrow-transplanted Apoe À/À mice (99.5 ± 0.3% versus 99.6 ± 0.2%, respectively). There was no significant difference in the blood pressure among the transplanted mice groups ( Supplementary  Table 1b ). However, the number of bone marrow-derived inflammatory cells (GFP + CD45 + double-positive cells) in the aortic wall was significantly lower in chimeric AngII-treated Apoe À/À Ppia À/À mice compared with chimeric AngII-treated Apoe À/À mice ( Fig. 3a-c) . We also measured the number of GFP + CD45 À cells in AAA lesions after AngII infusion. The number of GFP + CD45 À cells in the aortic wall was significantly lower in chimeric AngII-treated Apoe À/À Ppia À/À mice compared with chimeric AngII-treated Apoe À/À mice (15.2 ± 15.3 cells per mm 2 versus 60.9 ± 28.9 cells per mm 2 , respectively, P o 0.05). Recent studies have shown that both nonhematopoietic cells (CD45 À ) and hematopoietic cells (CD45 + ) are mobilized from the bone marrow and contribute to remodeling of the vascular wall 28 . The presence of GFP + CD45 À cells in AngII-induced AAA lesions suggests that CypA has a crucial role in recruiting nonhematopoietic cells from the bone marrow. The number of bone marrow-derived macrophages (GFP + Mac-1 + ) found in AAA lesions was also significantly lower in Apoe À/À Ppia À/À recipient mice (Supplementary Fig. 3a -c online).
We frequently observed migration of bone marrow-derived cells into the media of the aorta in Apoe À/À recipient mice ( Fig. 3d) . In contrast, there were few GFP + cells in the aortic media of Apoe À/À Ppia À/À recipient mice ( Fig. 3e,f ), suggesting the importance of VSMC-derived CypA for inflammatory cell migration. Furthermore, microvessel density, as assessed by platelet/endothelial cell adhesion molecule-1 (PECAM-1) staining, was significantly reduced in Apoe À/À Ppia À/À recipient mice ( Fig. 3d ,e,g), supporting the concept that the decrease in inflammatory responses in Apoe À/À Ppia À/À mice is due to CypA deficiency in vascular cells. Consistent with this idea, the incidence of AAA was 56% in Ppia +/+ marrow-transplanted Apoe À/À mice versus 0% in Apoe À/À Ppia À/À mice after transplantation of Ppia +/+ bone marrow cells ( Fig. 3h ). Finally, we generated chimeric mice with Ppia À/À bone marrow ( Supplementary Fig. 3d ). The incidence of AAA was 60% in Ppia À/À marrow-transplanted Apoe À/À mice, similar to that in nontransplanted Apoe À/À mice, and the incidence of AAA was 0% in Ppia À/À marrow-transplanted Apoe À/À Ppia À/À mice, as it was in nontransplanted Apoe À/À Ppia À/À mice ( Supplementary Fig. 3d ). Taken together, these data suggest that CypA expression by vascular cells, rather than bone marrow-derived cells, is crucial for the development of AAA.
CypA deficiency prevents AngII-induced MMP activation AAA development and aortic rupture depend on macrophage-derived MMP-9 and VSMC-derived MMP-2 (refs. 24, 29, 30) , which are enzymatically cleaved and activated by membrane type-1 MMP CypA deficiency reduces AngII-induced inflammatory cell accumulation and microvessel formation. (a,b) Representative CD45 staining of suprarenal aortas from Apoe À/À and Apoe À/À Ppia À/À mice infused with AngII for 4 weeks.
(c) Number of migrating CD45 + cells in the aortic wall in Apoe À/À (n ¼ 9) and Apoe À/À Ppia À/À (n ¼ 7) mice. *P o 0.01 compared with Apoe À/À mice. (d-g) Representative immunostaining of a-smooth muscle actin (a-SMA) and Ki67 (a marker for proliferation) in suprarenal aortas from Apoe À/À (d,e) and Apoe À/À Ppia À/À (f,g) mice infused with AngII for 4 weeks. e and g are higher magnification images of the boxed areas in d and f, respectively. (h) Number of proliferating microvessels in the aortic wall. *P o 0.01 compared with Apoe À/À mice. (i) Immunoblots to assess the secretion of CypA from mouse VSMCs in response to AngII with or without pretreatment by the Rho kinase inhibitor Y27632 (30 mmol l À1 ) or simvastatin (30 mmol l À1 ) for 30 min. The experiment was repeated three times. IB, immunoblot; CM, conditioned medium; TCL, total cell lysate.
(MT1-MMP) 31 . Secreted CypA may activate MMPs through the extracellular MMP protein inducer (EMMPRIN) 32 . Therefore, we anticipated that MMP activity would be decreased in the absence of CypA. We performed western blotting for MMP-2 using a MMP-2specific mouse monoclonal antibody that recognizes the 72-kDa latent and the 66-kDa active forms of MMP-2. We observed markedly reduced MMP-2 activity in AngII-treated Ppia À/À VSMCs compared to wild-type (WT, Ppia +/+ ) VSMCs ( Supplementary Fig. 4a online). MT1-MMP abundance in the membrane fraction was substantially increased in AngII-treated WT VSMCs compared to AngII-treated Ppia À/À VSMCs ( Supplementary Fig. 4b ), suggesting a key role for CypA in MT1-MMP translocation to the cell membrane. Consistent with these findings, AngII-induced activation of MT1-MMP was significantly (P o 0.01) elevated in WT VSMCs compared with Ppia À/À VSMCs ( Supplementary Fig. 4c ). We next studied MMP levels in the aortas of Apoe À/À and Apoe À/À Ppia À/À mice. Basal expression of MT1-MMP was low in the aortas of mice of both genotypes (Fig. 4a) . After AngII infusion, MT1-MMP expression was considerably increased in the aortas of both Apoe À/À and Apoe À/À Ppia À/À mice, but this increase was markedly attenuated in Apoe À/À Ppia À/À mice (Fig. 4a) . In organ culture, conditioned medium obtained from aortas from AngIItreated Apoe À/À mice showed high levels of proMMP-9, proMMP-2 and activated MMP-2 by zymography ( Fig. 4b) . In contrast, conditioned medium from aortas from AngII-treated Apoe À/À Ppia À/À mice lacked MMP expression or activity (Fig. 4b) . In situ zymography supported these observations: MMP activity, which was negligible in saline-treated aortas, was much higher in the medial and adventitial layers of AngII-treated aortas from Apoe À/À mice as compared with Apoe À/À Ppia À/À mice (Fig. 4c,d) . Notably, the ruptured aortas of Apoe À/À mice revealed a tremendously high level of MMP activity, especially in the false lumen ( Fig. 4c) .
To compare the properties of VSMCs in AAA-prone versus AAA-resistant areas, we collected and cultured VSMCs from the thoracic, suprarenal and infrarenal aortas and measured MMP activities in response to treatment with AngII ( Fig. 4e ). In cells from aortas treated with saline, there was no difference among the different types of VSMCs in MMP-2 activity, as assessed by gelatin zymography (Fig. 4e ). AngII treatment substantially increased MMP-2 activity in Apoe À/À VSMCs, especially in VSMCs from the suprarenal aorta ( Fig. 4e) . In contrast, the induction of MMP-2 activity by AngII was substantially attenuated in Apoe À/À Ppia À/À VSMCs, regardless of the aortic location (Fig. 4e) . Treatment of VSMCs with CypA augmented MMP activity by approximately twofold, as assessed by in situ zymography (Fig. 4f,g) , demonstrating the importance of extracellular CypA for MMP activation in VSMCs. Consistent with these data, in situ zymography showed that active MMP expression was much greater in the media of suprarenal aorta than in that of infrarenal or thoracic aorta in AngII-treated mice ( Supplementary  Fig. 5a-c online) . These in vivo and in vitro data demonstrate that CypA in VSMCs is crucial for activation of MMPs.
CypA deficiency prevents AngII-induced ROS production We next investigated the mechanism by which CypA deficiency decreases MMP expression, secretion and activation. ROS have a crucial role in activating VSMC MMPs 33 via a pathway dependent upon the p47 phox -containing NADPH oxidase 34 . Therefore, we studied the effect of CypA deficiency on VSMC ROS production induced by AngII. Activation of ERK1/2 by AngII was not markedly different between Ppia +/+ and Ppia À/À VSMCs (data not shown). In response to treatment with AngII for 4 h, ROS production in Ppia +/+ mouse VSMCs, as assessed by dichlorofluorescein staining, increased by 12-fold ( Fig. 5a,b) . Ppia À/À VSMCs showed significantly less ROS induction ( Fig. 5a,b ). Furthermore, treatment of Ppia +/+ VSMCs with CypA for 4 h significantly (P o 0.01) augmented ROS production ( Fig. 5c,d ), suggesting that CypA secretion induced by AngII promotes ROS production.
To evaluate the effect of CypA deficiency on ROS generation in vivo, we incubated aortic sections with dihydroethidium, which, in the presence of superoxide, forms the highly fluorescent molecule oxyethidium. ROS production was very low in aortas from both salinetreated Apoe À/À and Apoe À/À Ppia À/À mice (Fig. 5e) . After mice were treated with AngII for 7 d, oxyethidium fluorescence was markedly increased in Apoe À/À mouse aortas (Fig. 5e,f) . In contrast, ROS production was not induced by AngII in aortas from AngII-treated Apoe À/À Ppia À/À mice (Fig. 5e,f) . Taken together, these in vivo (Fig. 5e,f) and in vitro (Fig. 5a,b) data suggest that AngII-induced ROS production in VSMCs is enhanced by both intracellular and extracellular CypA.
VSMC-derived CypA promotes AAA formation in vivo
To provide further evidence that VSMC-derived CypA regulates ROS production and MMP activity, we used VSMC-restricted CypA-overexpressing mice (VSMC-Tg mice). We previously showed that CypA expression is approximately threefold higher in arteries of VSMC-Tg mice compared to WT mice 35 . In saline-infused mice, there was no difference in oxyethidium fluorescence between WT, Ppia À/À and VSMC-Tg aortas (Fig. 6a) . However, after AngII-infusion for 7 d, oxyethidium fluorescence was markedly higher in VSMC-Tg aortas than in WT (intermediate) or Ppia À/À (lowest) aortas (Fig. 6a) .
There was no difference in basal MMP activity between WT, Ppia À/À and VSMC-Tg aortas in saline-infused mice (Fig. 6b) . However, after AngII infusion, MMP activity was considerably higher in VSMC-Tg aortas than in WT (intermediate) or Ppia À/À (lowest) aortas (Fig. 6b) . We next assayed AngII-mediated activation of MMP-2 and MMP-9 by gel zymography (Fig. 6c) . The abundance of active MMP-2 in the conditioned medium after organ culture of aorta was significantly augmented for VSMC-Tg aortas compared with WT aortas and significantly decreased for Ppia À/À aortas (Fig. 6c,d) . These results were supported by a similar experiment using cultured VSMCs collected from mouse aorta: MMP-2 activity was substantially augmented in VSMCs from VSMC-Tg mice compared with those from WT or Ppia À/À mice (Fig. 6e) . These data support the concept that VSMC-derived CypA is a key mediator of AngII-induced MMP-2 activation.
To provide additional support for the pathogenic role of CypA in AAA formation, we investigated the effects of AngII infusion in VSMC-Tg mice. We attempted to cross the VSMC-Tg onto the Apoe À/À background but did not obtain any viable pups, preventing us from directly testing the effect of CypA overexpression in VSMCs on AAA formation. In mice with an Apoe +/+ genetic background, there was no marked difference in aortic weight and diameter between Ppia À/À , WT and VSMC-Tg mice in control saline-infused mice (data not shown). In response to AngII infusion, the maximum aortic diameter increased markedly in VSMC-Tg mice by approximately twofold compared to Ppia À/À mice or WT mice (Fig. 6f) , with a highly significant increase in AAA incidence (Fig. 6g) . These results support the idea that VSMC-derived CypA is crucial for MMP-2 activation and AAA formation induced by AngII infusion. Finally, we evaluated the role of CypA in human AAA lesions ( Supplementary Fig. 6 online) . CypA was highly expressed throughout the aortic wall of AAA lesions, especially in areas that express active MMP ( Supplementary Fig. 6a,b) . We performed organ culture to determine the effect of AngII treatment on CypA secretion. AngII substantially increased secretion of CypA from human AAA lesions ( Supplementary Fig. 6c ). We next collected VSMCs from human AAA tissues and found that they expressed CypA at high levels ( Fig. 6d,e ). In response to AngII, MMP activity was also strongly increased (Supplementary Fig. 6f,g) . Using gel zymography, this activity was shown to be mediated by MMP-2 ( Supplementary Fig. 6h,i) . Treatment with cyclosporine A markedly decreased MMP-2 activation, demonstrating a key role for the peptidyl-prolyl cis/trans isomerase activity of CypA ( Supplementary Fig. 6h,i) . These results suggest a crucial contribution by CypA to MMP activation in human AAA lesions.
DISCUSSION
Our major finding is that CypA is an essential mediator of AAA formation. We characterized four pathological mechanisms by which vascular CypA promotes AAA formation ( Supplementary Fig. 7 online). First, AngII-induced ROS promote secretion of CypA and proMMP-2. Second, secreted extracellular CypA contributes to ROS production synergistically with AngII in VSMCs. Third, CypA promotes activation of MMP-2 by inducing MT1-MMP activation and augmenting ROS generation. Last, CypA stimulates recruitment of CD45 + inflammatory cells. The source of CypA responsible for AAA formation seems to be cells in the vessel wall, especially VSMCs, as no AAAs were observed in Apoe À/À Ppia À/À mice after transplantation with Ppia +/+ bone marrow cells. Also, overexpression of CypA specifically in VSMCs enhanced vascular ROS production, MMP activation and AAA formation. Therefore, we propose a key role for vascular CypA in AAA formation and other cardiovascular diseases associated with inflammation. VSMCs seem to be essential for AngII-induced AAA formation. Expression of the AngII type 1a receptor, which is responsible for CypA secretion, ROS generation and MMP activity, is highest in VSMCs 36 . We found that in situ measurements of ROS generation and MMP activity were highest in medial cells that stained for a-SMA. Furthermore, cultured VSMCs from transgenic mice and human AAA lesions recapitulated our in situ findings of increased ROS and MMP activation. Finally, bone marrow transplantation experiments showed a minor role for hematopoietic cells in AAA formation in terms of CypA expression. Our data suggest that VSMC-derived CypA initiates AAA formation by promoting accumulation of macrophages. Apoe À/À Ppia À/À mice had markedly attenuated vascular ROS production, MMP activation and MCP-1 secretion, resulting in decreased macrophage accumulation. Overexpression of CypA in VSMCs enhanced ROS production and MMP activation and caused AAA formation even in Apoe +/+ mice. Finally, transplantation of bone marrow cells from Ppia +/+ mice into Apoe À/À Ppia À/À mice did not induce AAA formation, indicating that it is the Ppia status of cells resident in the vessel wall that affects AAA formation.
Our data show that extracellular CypA induces ROS production in VSMCs, which is consistent with our previous report that extracellular CypA stimulates at least three signaling pathways (ERK1/2 and Akt and Janus kinases) in VSMCs 19 . These signaling pathways have been shown to be crucial in ROS production 2,3 . Furthermore, ROS stimulate secretion of CypA from VSMCs 19, 21 . These reports and our current data suggest that CypA has a crucial role in the matrixdegrading and proliferative functions of VSMCs by augmenting ROS generation. AngII is thought to induce the generation of ROS, thereby activating MMPs 26 and thus leading to the onset of vascular inflammatory cell migration and AAA formation 7, 16, 24 .
In our experiments, CypA deficiency decreased both secretion of proMMP-2 and MMP-2 and expression of MT1-MMP, all of which can be explained by reduced ROS production. Additionally, AngII has been shown to generate ROS and activate MMP-2 in a p47 phoxdependent manner 7, 15, 37 . VSMC-derived MMP-2 promotes degradation of collagen and elastin, contributing to AAA formation 30, 31 . Expression of MT1-MMP is important for activation of MMP-2 in AngII-induced AAA formation 38 . Aside from enzymatic cleavage and activation of MMP-2 by cell surface-expressed MT1-MMP 31 , ROS have also been shown to directly activate MMP-2 33 . AAA formation results from the synergistic activation of ROS production, MT1-MMP and MMP-2. Therefore, CypA seems to be a central mediator of AngII-mediated AAA formation.
The identification of CypA as a mediator of tissue damage associated with inflammation and oxidative stress provides insight into the mechanisms underlying several therapeutic interventions. For example, the Rho kinase inhibitor Y27632 and simvastatin considerably reduced CypA secretion from VSMCs in this study. Rho kinase is a major therapeutic target in cardiovascular disease 39 , and Rho kinase inhibition has been reported to reduce AngII-induced AAA formation 40 . AngII type 1 receptor blockers and angiotensin-converting enzyme (ACE) inhibitors have been shown to prevent AAA formation in mice [41] [42] [43] . In light of our results, reduced CypA secretion may partially contribute to the therapeutic effect of these drugs on AAA formation. Because inflammation and oxidative stress contribute to tissue damage in several situations, such as ischemia-reperfusion injury in the brain, heart and kidney, future studies of CypA-mediated function in appropriate models may reveal a major role for CypA in these conditions. EMMPRIN, a putative CypA receptor, was identified as a tumor cell membrane protein that is expressed in VSMCs and activated by ROS and that stimulates MMP production 44 . A recent study showed ROSdependent increases in EMMPRIN expression 45 , which may be activated by binding of extracellular CypA 32 . Moreover, it has been shown that EMMPRIN is strongly expressed in human AAA lesions 46 . Therefore, it is logical to propose that agents that prevent CypA binding to its receptors may have therapeutic potential. In summary, these previous reports and our current study suggest that extracellular CypA and its receptor(s) represent new therapeutic targets, particularly for AAA progression.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 
